Foundation Medicine, Agios developing diagnostics for cancer drugs

04/5/2013 | GenomeWeb Daily News (free registration)

Foundation Medicine and Agios Pharmaceuticals agreed to jointly develop companion diagnostics for the latter's experimental cancer drugs. The two companies will seek to identify genomic mutations to determine which patients will benefit from Agios' new cancer metabolism inhibitors that target tumors with mutated IDH1 or IDH2 metabolic enzymes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA